Histone deacetylase inhibitors in clinical development

ISSN： 1354-3784

Source： Expert Opinion on Investigational Drugs, Vol.13, Iss.1, 2004-01, pp. : 21-38

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The clinical development of histone deacetylase inhibitors as targeted anticancer drugs

By Marks Paul A

Expert Opinion on Investigational Drugs, Vol. 19, Iss. 9, 2010-09 ,pp. : 1049-1066

Informa Healthcare

Access to resources Recommend Favorite

Histone deacetylase inhibitors: from target to clinical trials

By Kelly William K O’Connor Owen A Marks Paul A

Expert Opinion on Investigational Drugs, Vol. 11, Iss. 12, 2002-12 ,pp. : 1695-1713

Informa Healthcare

Access to resources Recommend Favorite

Histone deacetylase inhibitors: discovery and development as anticancer agents

By Marks Paul A Dokmanovic Milos

Expert Opinion on Investigational Drugs, Vol. 14, Iss. 12, 2005-12 ,pp. : 1497-1511

Informa Healthcare

Access to resources Recommend Favorite

Modifying histones to tame cancer: clinical development of sodium phenylbutyrate and other histone deacetylase inhibitors

By Gore S.D. Carducci M.A.

Expert Opinion on Investigational Drugs, Vol. 9, Iss. 12, 2000-12 ,pp. : 2923-2934

Informa Healthcare

Access to resources Recommend Favorite

Histone deacetylase inhibitors

By Price Steve Dyke Hazel J

Expert Opinion on Therapeutic Patents, Vol. 17, Iss. 7, 2007-07 ,pp. : 745-765

Informa Healthcare

Access to resources Recommend Favorite